Welcome to our dedicated page for Organogenesis Hldgs SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Organogenesis Holdings Inc. (ORGO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer, Organogenesis submits periodic and current reports that describe its financial condition, operating results, clinical programs, governance matters, and capital structure.
Through this page, users can review Form 10-K annual reports and Form 10-Q quarterly reports, which include audited or reviewed financial statements, segment information for its regenerative medicine operations, and detailed discussions of risk factors, research and development spending, and market dynamics for its Advanced Wound Care and Surgical & Sports Medicine product categories. These filings also outline how the company reports net product revenue, operating expenses, cash and cash equivalents, and information about Series A redeemable convertible preferred stock.
Current reports on Form 8-K document material events such as quarterly earnings releases, updates on the Phase 3 randomized controlled trials of ReNu for knee osteoarthritis, plans to request or initiate a Biologics License Application (BLA), and stockholder meeting results. For example, Organogenesis has used Form 8-K to furnish press releases on ReNu clinical data, to describe its intention to pursue a BLA submission pathway, and to report the outcomes of its annual meeting, including director elections and advisory votes on executive compensation.
Investors can also use this page to track governance and capital structure disclosures, including approvals related to the potential issuance of additional Class A common stock upon conversion of Series A Convertible Preferred Stock under Nasdaq listing rules. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify important financial metrics, clinical program updates, and regulatory milestones without reading every line of each report.
Organogenesis Holdings Inc. reported an insider stock transaction by a company director. On 12/16/2025, the director sold 200,000 shares of Class A Common Stock in open-market trades at a weighted-average price of $5.1353 per share, with individual trade prices ranging from $5.10 to $5.24.
After this sale, the director directly beneficially owns 2,565,591 shares of Class A Common Stock. In addition, the director has indirect beneficial ownership through three trusts holding 918,680 shares, 7,928,570 shares, and 335,719 shares of Class A Common Stock, respectively.
Organogenesis Holdings Inc. reported Q3 2025 results showing stronger profitability. Total revenue was $150.864M (net product revenue $150.487M), up from $115.177M a year ago. Income from operations rose to $20.727M, and net income reached $21.567M, or $0.11 per diluted share. Advanced Wound Care drove the quarter with $141.451M, while Surgical & Sports Medicine contributed $9.036M.
Year to date, revenue was $338.562M versus $355.387M in 2024, with a net loss of $6.668M. Cash and cash equivalents were $63.745M and operating cash flow was an outflow of $49.729M for the nine months. Accounts receivable increased to $168.783M and inventories to $39.583M. The company recorded $0.603M of grant income tied to the Smithfield facility buildout and ended the quarter with deferred grant income on the balance sheet.
The revolving credit facility was reduced to $75M with updated covenants; there were no outstanding borrowings. Management flagged potential Medicare LCD changes effective January 1, 2026 that would limit coverage for several products. In clinical updates, a second Phase 3 ReNu knee OA trial did not meet its primary endpoint; an FDA meeting is scheduled for December 12, 2025 to discuss a BLA using combined data.
Organogenesis Holdings (ORGO) reported that it announced its fiscal third-quarter results for the period ended September 30, 2025, via a press release dated November 6, 2025. The company furnished the press release as Exhibit 99.1 to an 8-K.
The company stated that the press release is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. For full details, readers are directed to the furnished Exhibit 99.1.
Organogenesis Holdings Inc. (ORGO) insider activity: A director and 10% owner reported Form 4 transactions. An affiliated trust purchased 251,001 shares of Class A common stock on 05/14/2025 at a weighted-average price of $3.0878 and 107,494 shares on 05/15/2025 at a weighted-average price of $2.9862. The same trust sold 4,156 shares on 06/09/2025 at a weighted-average price of $3.5003 and 18,620 shares on 06/10/2025 at a weighted-average price of $3.5583.
Following the reported transactions, holdings included 335,719 shares indirectly by the Glenn Nussdorf 10 Year Follow On Trust and 3,065,591 shares held directly. The filing notes that the sales on 06/09/2025 and 06/10/2025 were matchable with a 05/15/2025 purchase under Section 16(b), and the reporting person paid the issuer $13,285.24, comprising $12,971.78 in profit plus $313.46 in interest.
Organogenesis Holdings, Inc. filed a Form 8-K reporting a material event that includes a press release dated
The filing text supplied here contains no actual trial results, financial figures, forward-looking statements, or additional narrative about the ReNu data, and therefore does not disclose outcomes, metrics, or impacts on operations or finances.
Organogenesis Holdings, Inc. Schedule 13G shows First Light Asset Management, LLC and Mathew P. Arens report joint beneficial ownership of common stock. The Manager is reported to beneficially own 8,061,404 shares (representing 6.35% of the class) while Mr. Arens is reported to beneficially own 8,309,404 shares (6.55%), including 231,000 shares held directly with sole voting and dispositive power. The filing is made under Rule 13d-1(b) and includes a joint filing agreement.
Organogenesis Holdings Inc. reporting person Brian Grow, the company's Chief Commercial Officer, disclosed transactions on 08/11/2025 involving both stock-option exercise and share transactions. The filing shows the exercise of a stock option that resulted in 4,060 Class A common shares acquired at an exercise price of $2.47, and it states that 100% of the shares subject to the option are fully vested and exercisable.
The Form 4 also reports a transaction involving 2,173 Class A common shares at a reported price of $4.615. The filing lists beneficial ownership figures of 674,550 and 672,377 Class A common shares on the respective lines, indicating the reporting person continues to hold hundreds of thousands of shares following these transactions.
Organogenesis Holdings Inc. (ORGO) – Schedule 13D/A (Amendment 10) filed 06/24/2025
The filing updates beneficial ownership information for a long-standing reporting group comprised of company founders, related trusts and affiliated investment vehicles. No purchase or sale prices are disclosed in the excerpt; however, the cover page states that the amendment was triggered by an event on June 24 2025.
Key ownership positions disclosed
- Alan A. Ades: 22,319,836 shares (17.6% of Class A common), of which 11.2 million are held with sole voting/dispositive power and 11.1 million with shared power.
- Albert Erani: 17,920,498 shares (14.1%) – approximately 6.8 million sole and 11.1 million shared.
- Glenn H. Nussdorf: 11,912,841 shares (9.4%) – 11.0 million sole, 0.9 million shared.
- Dennis Erani: 10,043,701 shares (7.9%) – 1.3 million sole, 8.7 million shared.
- Organo PFG LLC: 8,279,490 shares (6.5%) – all sole voting/dispositive.
- Other entities & individuals: Organo Investors LLC (2.9 million / 2.2%), Alan Ades 2014 GRAT (3.1 million / 2.4%) and Starr Wisdom (20,000 / <0.1%).
Based on the amounts reported, the group collectively controls approximately 76.4 million Class A shares. Although total shares outstanding are not provided in the excerpt, each of the first four individuals continues to exceed the 5% reporting threshold, indicating significant insider alignment with shareholders. The amendment does not specify whether positions increased or decreased relative to the prior filing.
No financial performance metrics, transaction prices or strategic commentary accompany the ownership data, suggesting that the filing is largely administrative—updating share counts and voting arrangements among a pre-existing insider group.
Organogenesis Holdings Inc. (Nasdaq: ORGO) filed an 8-K covering the results of its 23 June 2025 Annual Meeting and a preferred-stock director election.
Board & Executive Matters
- Series A Convertible Preferred holders unanimously re-elected Garrett Lustig to the Board.
- All nine management-nominated directors were re-elected; the highest support was 72.4 million votes (95.8% of votes cast) for Gilberto Quintero, while the lowest was 68.9 million (93.9%) for Jon Giacomin.
- Say-on-Pay advisory resolution passed with 91.4% support (67.1 m for / 6.3 m against).
Capital Structure Proposal
- Shareholders approved—by 45.4 m for vs. 2.7 m against—the potential issuance of >20% of outstanding Class A shares upon conversion of Series A Preferred below Nasdaq “minimum price,” a step that could be deemed a change-of-control under Rules 5635(b)/(d).
Audit Matters
- RSM US LLP was ratified as independent auditor for FY 2025 with 96.4% support (103.6 m for / 3.9 m against).
Quorum: 107.5 million Class A votes were present (inclusive of 25.4 m as-converted preferred shares, subject to Nasdaq’s 19.99% cap).
The filing is largely routine governance disclosure; however, the preferred-stock conversion approval introduces potential future dilution that current shareholders should monitor.
FAQ
What is the current stock price of Organogenesis Hldgs (ORGO)?
What is the market cap of Organogenesis Hldgs (ORGO)?
